<DOC>
	<DOCNO>NCT00327522</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity two dos GSK Biologicals ' 11 PCV vaccine give healthy subject age 18 40 year .</brief_summary>
	<brief_title>Safety Immune Response Study Investigational Pneumococcal Vaccine .</brief_title>
	<detailed_description>The study open subject receive two vaccine dos GSK Biologicals ' 11 PCV vaccine . Five blood sample take : prior one month vaccine dose , 2 week dose 2 .</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>healthy male female 18 40 year age 23valent pneumococcal polysaccharide vaccine naive adult . Previous vaccination Streptococcus pneumoniae . History pneumonia within 3 year prior first vaccination Any confirm suspected immunosuppressive immunodeficient condition All malignancy ( exclude nonmelanic skin cancer ) lymphoproliferative disorder diagnose treat actively past 5 year . Subjects document anaemia irondeficiency ( Hemoglobin level 10 % low limit normal ) History administration experimental/licensed vaccine contain similar adjuvant . History chronic alcohol consumption and/or drug abuse . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>